Novartis: Phase III Data On Oral Remibrutinib Shows Long-Term Efficacy & Safety In Chronic Urticaria
31/5 04:37
(RTTNews) - Novartis (NVS) announced new data that confirm the long-term efficacy and safety of remibrutinib, a highly selective Bruton's tyrosine kinase (BTK) inhibitor, in chronic spontaneous urticaria or CSU....